LOW LEVELS OF GROWTH DIFFERENTIATION FACTOR 11 AND HIGH LEVELS OF ITS INHIBITOR FOLLISTATIN-LIKE 3 ARE ASSOCIATED WITH ADVERSE CARDIOVASCULAR OUTCOMES IN HUMANS